V3V Share Price Performance
€2.82
-2.33 (-45.24%)
56.6% undervalued intrinsic discount
€6.50
Fair Value
Price €2.82
AnalystConsensusTarget €6.50
Fair Value€6.50
Share Pricen/a
Narrative Update • Jun 26
FamiCord AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
V3V Community Narratives
AN
Fair Value
·Fair Value €6.5 56.6% undervalued intrinsic discount
Placenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Placenta Banking Expansion Will Drive Long Term Stem Cell Demand Across Europe
FamiCord is betting that placenta banking—an option many parents and doctors find easier to understand—can help more families choose long-term sample storage and lift what each customer spends. But the story hinges on overcoming falling birth rates, tough rules in key countries, and lingering skepticism after past failures in the industry.Read more
AN
€6.5
56.6% undervalued intrinsic discount
Fair Value
Profit Margin
2.98%
Future PE
46.74x
Price in 2029
€7.41
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
V3V: Higher Discount Rate Will Still Support Bullish 2026 Revenue Outlook
Fair Value: €6.5 56.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
FamiCord AG Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 28, 2026
- -0.26
- 58.63%
- -5.20%
- 310.5%
About V3V
- Founded
- 1997
- Employees
- 723
- CEO
- WebsiteView website
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
